ArticleMolecular cancer therapeutics2016

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Thomas C Beadnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.